Based on previous findings, we hypothesize that the integration of LPA1 antagonist mediated anti-fibrotic activities with A20 mediated anti-inflammatory activities may suppress fibroblast activation, and thereby limit the fibrotic responses and IPF development. Here, LPAR1 is linked to idiopathic pulmonary fibrosis.